Third World Guinea Pigs - Dengue Vaccine to be tested in India
Dengue vaccine to be tested in India
French health care giant Sanofi Pasteur will soon test a vaccine against dengue fever in India amid concerns about the increasingly global spread of the disease, reports said on Monday. The vaccine will be tried on about 120 adults followed by trials on children before it will be made available internationally, which can be as soon as 2015, the Times of Indi
French health care giant Sanofi Pasteur will soon test a vaccine against dengue fever in India amid concerns about the increasingly global spread of the disease, reports said on Monday. The vaccine will be tried on about 120 adults followed by trials on children before it will be made available internationally, which can be as soon as 2015, the Times of Indi
a newspaper said.
"Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon," Sanofi's CEO Christopher Viehbacher was quoted as saying.
Dengue causes a flu-like illness for most victims but one of its strains can cause life-threatening internal bleeding.
There is no licensed vaccine to protect against dengue. Efforts to develop one have been complicated by the fact that there are four different strains, all of which may circulate in an outbreak zone.
Dengue also seems to be exclusive to humans, which means it is impossible to test vaccines on lab animals first.
Jean Lang, head of the vaccine's research and development programme, said Sanofi had been asked to conduct "phase two safety trials" in India by the national drug controller.
http://
In a Setback, Sanofi’s Dengue Fever Vaccine Falls Short of Its Goal
The leading candidate to become the world’s first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world’s population.
The trial, conducted by Sanofi and Thailand’s Mahidol University, involved 4,000 schoolchildren, ages 4 to 11, in Thailand’s Ratchaburi Province. Two-thirds of the children received three injections of the vaccine over the course of a year, while the other third received three injections either of a rabies vaccine or a placebo.
Among children who got all three doses of either the vaccine or the control, there were 45 cases in the vaccinated group, representing 1.8 percent of that group, and 32 cases, or 2.6 percent, in the control group. The difference was not statistically significant. Using a different calculation the vaccine reduced the risk of getting dengue by 30 percent, well below the study’s goal of 70 percent.
http://www.nytimes.com/
"Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon," Sanofi's CEO Christopher Viehbacher was quoted as saying.
Dengue causes a flu-like illness for most victims but one of its strains can cause life-threatening internal bleeding.
There is no licensed vaccine to protect against dengue. Efforts to develop one have been complicated by the fact that there are four different strains, all of which may circulate in an outbreak zone.
Dengue also seems to be exclusive to humans, which means it is impossible to test vaccines on lab animals first.
Jean Lang, head of the vaccine's research and development programme, said Sanofi had been asked to conduct "phase two safety trials" in India by the national drug controller.
http://
In a Setback, Sanofi’s Dengue Fever Vaccine Falls Short of Its Goal
The leading candidate to become the world’s first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world’s population.
The trial, conducted by Sanofi and Thailand’s Mahidol University, involved 4,000 schoolchildren, ages 4 to 11, in Thailand’s Ratchaburi Province. Two-thirds of the children received three injections of the vaccine over the course of a year, while the other third received three injections either of a rabies vaccine or a placebo.
Among children who got all three doses of either the vaccine or the control, there were 45 cases in the vaccinated group, representing 1.8 percent of that group, and 32 cases, or 2.6 percent, in the control group. The difference was not statistically significant. Using a different calculation the vaccine reduced the risk of getting dengue by 30 percent, well below the study’s goal of 70 percent.
http://www.nytimes.com/
Нема коментара:
Постави коментар